Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 989-997

  Gori, Jennifer L ^a   Podetz Pedersen, Kelly ^a   Swanson, Debra ^a   Karlen, Andrea D ^a   Gunther, Roland ^a   Somia, Nikunj V ^a   McIvor, R Scott ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; ENHANCED GREEN FLUORESCENT PROTEIN; FLUOROURACIL; LENTIVIRUS VECTOR; METHOTREXATE; METHOTREXATE RESISTANT DIHYDROFOLATE REDUCTASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL MANIPULATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; EX VIVO STUDY; FEMALE; FLUORESCENCE; HEMATOCRIT; LYMPHOID CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIDOTES; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; DRUG RESISTANCE; GENETIC VECTORS; HEMATOCRIT; LENTIVIRUS; METHOTREXATE; MICE; MICE, INBRED C57BL; MUTATION; TETRAHYDROFOLATE DEHYDROGENASE; TRANSDUCTION, GENETIC;

EID: 34548062051     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123414     Document Type: Article

References (42)

1. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J, Traycoff CM, Bank A, Kato I, Ward M, et al. (2000) Efficient retrovirus-mediated gene transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6:652-658.
2. Agarwal S, Nikolai B, Yamaguchi T, Lech P, and Somia NV (2006) Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther 14:555-563.
3. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, and Sorrentino BP (1998) In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 4:1136-1143.
4. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakely RL, and Sorrentino BP (1997) Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90:3546-3554.
5. Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5-14.
6. Blakley RL and Benkovic SJ (1984) Folates and pterins, in Volume 1, Chemistry and Biochemistry of Folates, John Wiley & Sons, Inc., New York.
7. Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MAS, and Bertino JR (2004) Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther 10:574-584.
8. Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, and Bertino JR (2004) Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther 11:767-773.
9. Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, and Bertino J (2003) Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum Gene Ther 14:435-446.
10. Carr F, Medina WD, Dube S, and Bertino JR (1983) Genetic transformation of murine bone marrow cells to methotrexate resistance. Blood 62:180-185.
11. Corey CA, DeSilva AD, Holland CA, and Williams DA (1990) Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75:337-343.
12. + peripheral blood cells with O6-methylguaninine DNA methytransferase. Cancer Gene Ther 13:886-895.
13. Gori JL, Podetz-Pedersen K, Swanson D, Karlen AD, Somia NV, and McIvor RS (2006a) Chemoprotection of mouse marrow transplant recipients by ex vivo lentiviral transduction of murine tyr22 dihydrofolate reductase conferring resistance to methotrexate. Mol Ther 13:S299.
14. Gori JL, Podetz-Pedersen K, Swanson D, Karlen AD, Somia NV, and McIvor RS (2006b) Lentiviral transduction of murine tyr22 dihydrofolate reductase protects against methotrexate toxicity in mouse marrow transplant recipients. Exp Hematol 34:49.
15. Hanawa H, Hematti P, Keyvanfar K, Metzger ME, Krouse A, Donoahue RE, Kepes S, Gray J, Dunbar CE, Persons DA, et al. (2004) Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103:4062-4069.
16. Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J, and Kiem HP (2004) Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 103:3710-3716.
17. James RI, Diers MD, Wagner JE, and McIvor RS (1999) Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated by counterflow elutriation. Bone Marrow Transplant 24:815-821.
18. James RI, May C, Vagt MD, Studebaker R, and McIvor RS (1997) Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol 25:1286-1295.
19. James RI, Warlick CA, Diers MD, Gunther R, and McIvor RS (2000) Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. Blood 96:1334-1341.
20. Kurre P, Anandakumar P, Harkey MA, Thomasson B, and Kiem HP (2004) Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration. Mol Ther 9:914-922.
21. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
22. Lewis VA, Basso L, Blake N, Salo J, Lund TC, McIvor RS, and Orchard PJ (2003) Human nerve growth factor receptor and cytosine deaminase fusion genes. Hum Gene Ther 14:1009-1016.
23. Li MX, Banerjee D, Zhao SC, Schweitzer BI, Mineishi S, Gilboa E, and Bertino JR (1994) Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83:3403-3408.
24. May C, Gunther R, and McIvor RS (1995) Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 86:2439-2448.
25. May C, James RI, Gunther R, and McIvor RS (1996) Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity. J Pharmacol Exp Ther 278:1444-1451.
26. Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, Larson S, et al. (2002) Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc Natl Acad Sci U S A 99:3400-3405.
27. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, and Hayakawa T (2000) IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1:376-382.
28. Moe PJ and Holen A (2000) High dose methotrexate in childhood ALL. Pediatr Hematol Oncol 17:615-622.
29. Morris JA and McIvor RS (1994) Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. Biochem Pharmacol 47:1207-1222.
30. Morris JA, May C, Kim HS, Ismail R, Wagner JE, Gunther R, and McIvor RS (1996) Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants. Transgenics 2:53-67.
31. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, Sorrentino BP, and Nienhuis AW (1997) Retroviral mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitate scoring and selection of the transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90:1777-1786.
32. Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, Donahue RE, Dunbar CE, and Sorrentino BP (2004) Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103:796-802.
33. Peto R and Peto J (1972) Asymptotically efficient rank invariant procedures. J R Stat Soc A135:185-207.
34. Rivera GK, Evans WE, Kalwinsky DK, Mirro J, Ochs J, Dow LW, Abromowitch M, Pui CH, Dahl GV, Look AT, et al. (1985) Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol 3:201-206.
35. Sirotnak FM and Moccio DM (1980) Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse. Cancer Res 40:1230-1234.
36. Sweeney CL, Frandsen JL, Verfaillie CM, and McIvor RS (2003) Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res 63:1304-1310.
37. Tiscornia G, Singer O, and Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1:241-245.
38. Vinh DB and McIvor RS (1993) Selective expression of methotrexate- resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate. J Pharmacol Exp Ther 267:989-996.
39. Williams DA, Hsieh K, DeSilva A, and Mulligan RC (1987) Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166:210-218.
40. Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z, Peng T, Malehorn MT, Yang X, Civin CI, and Cheng L (2003) Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 7:827-838.
41. Zhao RCH, McIvor RS, Griffin JD, and Verfaillie CM (1997) Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood 90:4687-4698.
42. Zufferey R, Nagy D, Mandel RJ, Naldini L, and Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875.